Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy Experimental: Olaparib Olaparib tablets 300mg b.i.d. p.o. Intervention: Drug: Olaparib Placebo Comparator: Placebo Placebo tablets b.i.d. p.o. Intervention: Drug: Placebo
Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast that is one of the following phenotypes:
Patients with second primary malignancy. EXCEPTIONS are:
Kathy Queen, RN864firstname.lastname@example.org
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.